As of July 15, according to the SW-level industry, 92 biomedical companies have disclosed their performance forecast for the first half of 2024. Based on the lower limit of the net income to be reported, nearly 60% of the companies achieved growth, among which 22 companies doubled their net income on a year-on-year basis, with innovation and internationalization being important driving forces for the growth of corporate performance. In terms of realized net income, among the biomedical companies that have disclosed their performance forecast, Zhejiang NHU is expected to achieve a net profit attributable to shareholders of 2.077 billion yuan to 2.225 billion yuan in the first half of the year, an increase of 40% to 50% year-on-year, temporarily ranked first. In addition, the lower limit of net income to be achieved by ChuanNing Biotech, Zhejiang Huahai Pharmaceutical, Dong-E-E-Jiao, Shanghai Shyndec Pharmaceutical, Hepalink, and Jafron Biomedical is all over 0.5 billion yuan. (Shanghai Securities News)